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cardiac metabolism; electrophysiology; hyperpolarization-activated current inhibition CARDIAC REMODELING IS DEFINED as a series of genome expression, molecular, biochemical, electrophysiological, and interstitial modifications following myocardial injury, which progressively lead to changes in cardiac size, shape, function, and energetic metabolism (15) . Remodeling can occur in different physiological and pathological conditions and most often after severe myocardial infarction (MI). Clearly, progressive left ventricular (LV) dysfunction leading to cardiac remodeling is a multifactorial process, and there is much evidence to support the hypothesis that impaired energy metabolism plays a major role post-MI. This concept is based on the demonstration of energy deprivation in failing myocardium and on a series of metabolic changes that have been found in this condition, including abnormalities in substrate utilization, oxidative phosphorylation, and high-energy phosphorylation (25, 35) .
Heart rate (HR) is an important determinant of myocardial oxygen supply and demand, and therefore direct control of HR could be expected to influence the progression toward myocardial dysfunction and prevent or even reverse remodeling. Accordingly, ␤-blockade prevents further deterioration of post-MI remodeling, both in experimental preparations and in the clinical setting (12, 21, 27, 39) . As ␤-blockers have actions other than HR reduction (e.g., negative inotropism, blood pressure reduction, and/or prevention of the deleterious effects of catecholamines in the cardiomyocyte), it is unclear whether their antiremodeling effect is attributable to HR reduction or to their other effects. Ivabradine, the only agent presently available whose sole effect is HR reduction (5) , provides an opportunity to test the effects of "pure" HR reduction on remodeling.
Ivabradine inhibits the pacemaker hyperpolarization-activated current (I f ) that controls spontaneous diastolic depolarization in the sinus node and regulates HR (5, 8) with no effect on intra-atrial, atrioventricular, or intraventricular conduction times, myocardial contractility, or ventricular repolarization (40, 45, 46) . Clinically, ivabradine is indicated in stable angina pectoris (6, 37, 42) . A preliminary study in patients with reduced LV ejection fraction (LVEF) showed improvement in LV systolic and diastolic dimensions, suggesting containment of the remodeling process (26) . There are a few studies on the effects of ivabradine in a rat model of post-MI LV dysfunction induced by coronary artery ligation (18, 30, 31, 34) . Although these studies demonstrated beneficial cardiac effects of ivabradine, in terms of improvement in LV systolic and diastolic function and decreased interstitial and perivascular fibrosis, they did not address the impact of ivabradine on cardiac energy metabolism and ex vivo electrophysiological remodeling at the cellular level.
The aim of the investigations described here was to assess whether HR reduction with ivabradine can modulate the global phenotype of post-MI LV remodeling. To this end, we used a well-known animal model of cardiac remodeling in the rat to investigate the effect of ivabradine on a whole range of parameters associated with this phenotype, including LV dimension and dysfunction, hemodynamics, electrophysiological and interstitial remodeling, neuroendocrine activation, and energy metabolism.
MATERIALS AND METHODS
Study design. All animals were fed a standard rat chow diet and drinking water ad libitum and were maintained in an artificial 12-h: 12-h light/dark cycle. The study was conducted in compliance with the Guide for the Care and Use of Laboratory Animals published by NIH (publication no. 85-23, revised 1996) . According to the local laws, the study was approved by the local Ethics Committee in Ferrara and Gussago and submitted to the Italian Ministry of Health.
The experimental design is presented in Fig. 1 . Male anesthetized (Zoletil ϩ xylazine) Wistar rats (Charles River, Milan, Italy) (n ϭ 106, aged 8 -10 wk) underwent left anterior descending (LAD) coronary artery ligation according to Pfeffer et al. (36) . In 20 rats, the suture was tied loosely so as not to obstruct flow (sham rats; 14 for cardiac function and metabolism; 6 for electrophysiology). In the remaining 86 rats, the LAD was ligated to induce MI; 37 rats died within 24 h, 1 rat within 1 wk, and 6 rats were excluded because asynergy did not involve more than one segment. Seven days after surgery, animals with trivial infarct (Ͻ2 segments and normal LV dimensions) were discarded. The remaining 42 animals were allocated sequentially to two groups and received either no treatment (MI rats; 15 for cardiac function and metabolism; 5 for electrophysiology) or ivabradine (10 mg·kg Ϫ1 ·day Ϫ1 in vehicle drinking water ad libitum) (MIϩIVA rats; 17 for cardiac function and metabolism; 5 for electrophysiology) for 90 days. There was no between-group difference for heart weight/bodyweight ratio or cell membrane capacitance [ At 90 days, the animals were anesthetized by pentothal (30 mg/kg ip), weighed, and killed by guillotine. Liquid effusions in the pleural and peritoneal space were measured with a syringe. Heart and chambers (left and right ventricles and septum) were separated, weighed, and stored before analysis. Great caution was used to sample the intact muscle, away from the fibrotic border by inspection.
Echocardiography. Echocardiography was performed according to standard literature methods (33, 48) using a Vivid I echocardiograph (GE Medical Systems, Milan, Italy) equipped with 10S-RS and 8L-RS probes and 3S-RS transducer, in anesthetized rats at time 0 (start of treatment, i.e., 7 days after ligation) and 30 and 90 days. Posterior end-diastolic and end-systolic LV posterior wall thickness was measured, and volumes (LVESV and LVEDV), diameters (LVEDD and LVESD), and LVEF were calculated. This information was used to calculate stroke volume [SV ϭ AoVTI ϫ ( ϫ LVOD 2 /2), where AoVTI is the aortic velocity time integral ratio and LVOD is the LV outflow diameter] and cardiac output (CO ϭ SV ϫ HR). LV wall motion score index (LVWMSI) was calculated as the ratio of the sum of wall motion scores over total segments scored; the standard 16-segment model of the LV was applied (23) .
Cardiac biomarkers. After solid-phase extraction (Strata C-18-E; Phoenix Pharmaceuticals, Burlingame, CA), plasma atrial natriuretic peptide (ANP) was measured by radioimmunoassay, using competitive binding between unknown and 125 I-labeled peptides, according to the manufacturer's protocol. Brain natriuretic peptide (BNP) was measured by immunoenzymatic method according to the manufacturer's protocol. Myocardial collagen content was estimated via determination of hydroxyproline concentration in LV muscle. After dehydration and extraction, cardiac hydroxyproline was measured spectroscopically at 560 nm (3) . Further details are included in the supplemental material, which is available online at the American Journal of Physiology Heart Circulatory Physiology website.
Whole cell configuration patch-clamp technique. The excised hearts were mounted on a Langendorff apparatus for immediate isolation of single ventricular cardiomyocytes by enzymatic procedures, as described elsewhere (10) . The whole cell configuration of the patch-clamp technique was used to record action potential (AP) and ionic currents in the isolated myocytes (in at least n ϭ 8 cells per group per parameter), according to literature methods (10, 29) using a patch amplifier (Axopatch-200B; Axon Instruments, Sunnyvale, CA). APs were elicited at the rate of 0.2 Hz and sampled at 2 KHz. Cells were superfused with normal Tyrode solution (in mM: 140 NaCl, 5.4 KCl, 1.8 CaCl 2, 1.2 MgCl2, 10 D-glucose, and 5 HEPES adjusted to pH 7.3 with NaOH) to measure the AP or with properly modified Tyrode solution (normal Tyrode solution added with CdCl 2 0.5) for the transient outward current (Ito). Ito was evoked by depolarizing steps for 750 ms from Ϫ35 to ϩ55 mV from a holding potential of Ϫ70 mV, measured as peak outward current and normalized with respect to C m.
Kv4.2 and KChIP2 expression by quantitative RT-PCR.
LVs were frozen and stored at Ϫ80°C. Abundance of cardiac Kv4.2 and KChIP2 RNA transcript expression and an internal control transcript (GAPDH) was determined using quantitative RT-PCR. RNA was extracted using RNeasy Fibrous Tissue Mini Kit (cat. no 74704; Qiagen, Hilden, Germany), and first-strand cDNA synthesis was performed in a 100-l volume (2 g RNA and 2.5 mol random hexamer primers). qRT-PCR reactions were performed using 10 l of TaqMan Universal PCR Master Mix (Applied BioSystems, Foster City, CA) in a 20-l volume containing 50 ng cDNA and TaqMan primers and probes (Applied BioSystems cat. nos. Kv4.2, Rn005819412_m1; KChIP2, Rn00581941_m1; GAPDH, 452338E). Reactions were performed in triplicate using an ABI Prism 7500 Sequence Detection System (Applied BioSystems). Relative quantification of mRNA was determined using the 2 Ϫ⌬⌬CT method (28).
Cardiac energy metabolism. Creatine phosphate (CP) and purine nucleotides (ATP, ADP, and AMP) were extracted with 0.4 N HClO 4 from frozen LV biopsies, as described elsewhere (47) . Supernatants were assayed by high-pressure liquid chromatography (600 E multisolvent delivery system and a model 990 photodiode array detector; Waters, Milford, MA) (9) with spectroscopic detection at 205 nm for CP and 260 nm for nucleotides. The nucleotide levels were used to For parameters related to cardiac echocardiography and body weight, two-way analysis of variance was performed with repeated measures on time with SAS Mixed Procedure (with repeated statements; the correlation matrix selected by the Akaïke and Schwarz's Bayesian information criteria, the restricted maximum likelihood estimation method, and the Satterthwaite estimation method for degrees of freedom). For interpretation, the threshold for significance was fixed at 10% for interaction and 5% for principal effects. If the model (or treatment) multiplied by time interaction was significant, the model (or treatment) effect was considered at each fixed time. Otherwise, model (or treatment) effect was considered at all pooled times.
The distribution of the parameters CP, ATP, ADP, AMP, energy charge, remodeling index, hydroxyproline, body weight, and heart weight (all measured at time of death) was considered as Gaussian. In contrast, ANP had a log-normal distribution, and so a log 10 transformation of ANP was analyzed. A Student's t-test was performed for independent samples with SAS version 9, with a threshold for significance of 5%. For treatment effect (MIϩIVA vs. MI) only, fibrotic area, percentage asynergic area, wall motion score index, and pleural fluids were considered not normal and a nonparametric approach was chosen. An exact Wilcoxon test (Kruskal-Wallis test adapted to small samples) was performed using SAS version 9, with a threshold for significance of 5%.
Correlations between HR and each of CP, LVEF, ADP, hydroxyproline, and ANP, as well as between hydroxyproline and infarct area, were studied for MI and MIϩIVA animals. Because of small sample sizes and because those animals came from two different groups (MI and MIϩIVA), a nonparametric correlation was performed with Spearman correlation coefficient.
RESULTS
Hemodynamic cardiac remodeling. LAD ligation resulted in MI-induced phenotypic changes typical of LV remodeling (Fig. 2, A and B) . In untreated ligated animals (MI rats), there were constant increases in LVEDV and LVESV, which were significant at 90 days (P Ͻ 0.05 and P Ͻ 0.01, respectively, MI vs. sham). As expected, this resulted in a significant reduction in LVEF (P Ͻ 0.001, all times pooled, MI vs. sham, Fig. 2C ). HR was slightly elevated at randomization, most likely as a result of a compensatory mechanism following the acute damage of ligation (Fig. 2D) . In MI rats, HR was normalized by 30 days, returning toward sham levels. The MI rats also presented evidence of cardiac dysfunction with the development of heart failure (HF) ( Table 1) , as indicated by the changes in the following parameters vs. sham: 1) the presence of pleural effusion (14/15 MI rats, range 50 -2,000 l), 2) an increase in plasma ANP (150%; P Ͻ 0.001 vs. sham), and 3) an increase in cardiac hydroxyproline, a marker of fibrotic tissue modification with collagen deposition (300%, P Ͻ 0.05 vs. sham).
As expected, ivabradine induced a HR reduction of 12% from 30 days, which continued to the end of the study (P Ͻ 0.01 all times pooled vs. MI rats) (Fig. 2D ). HR reduction with ivabradine also resulted in reductions in LVEDV and LVESV, which occurred by 30 days of treatment and continued to 90 days (Ϫ17%, P ϭ NS and Ϫ30%, P ϭ NS vs. MI rats after 90 days) (Fig. 2, A and B) . At 90 days, LVEF was significantly improved by ivabradine treatment (15%, P Ͻ 0.01 vs. MI rats, Fig. 2C ), and the CO maintained (165 Ϯ 7 ml/min sham and 178 Ϯ 12 ml/min MIϩIVA, NS). There was no difference in cardiac function parameters for ivabradine-treated ligated animals vs. sham. Interestingly, there was a close relationship between HR and LVEF in all ligated animals (r ϭ Ϫ0.3971, P Ͻ 0.05). This improvement in cardiac function induced by treatment with ivabradine also resulted in less evidence for development of HF, as indicated by reductions in pleural effusion (5/17 rats, range 50 -300 l, P Ͻ 0.01 vs. MI rats), plasma BNP (Ϫ21%, P ϭ NS), ANP (33%, P ϭ 0.052), and cardiac hydroxyproline (33%, P ϭ NS) ( Table 1) . No change was observed in LVWMSI between MI rats (1.81 Ϯ 0.07 in untreated MI vs. 1.75 Ϯ 0.06 with MI rats treated with ivabradine), in line with the fact that ivabradine was administered after a week, with no effect, therefore, expected on infarct size.
Electrophysiological cardiac remodeling. In isolated LV cells of untreated ligated animals (MI rats), AP duration (APD) was homogeneously and significantly prolonged vs. sham (Table 2 ). This effect was attenuated with ivabradine at all points on the repolarization curve. I to density at 50 mV was significantly reduced in MI rats vs. sham (from 9.5 pA/pF in sham to 5.1 pA/pF in MI rats, P Ͻ 0.05) (Fig. 3, A and B) . This effect was partially, but significantly reversed by the administration of ivabradine (7.2 pA/pF in MIϩIVA; P Ͻ 0.05 vs. MI rats). Figure 3C shows that quantitative expression of mRNA Kv4.2, the major isoform coding for the ␣-subunit channel Values are means Ϯ SE. Data are from sham rats and ligated rats with no treatment (MI rats) or treated with 10 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 ivabradine in drinking water (MIϩIVA rats). MPD, maximum diastolic potential; APA, action potential amplitude; APD30, APD50, APD70, and APD90, action potential duration at 30%, 50%, 70%, or 90% repolarization, respectively. *P Ͻ 0.05 vs. sham. underlying the transient outward potassium current I to in the rat, is significantly decreased in untreated ligated MI rats (Ϫ43%, P Ͻ 0.05 vs. sham) and partially recovered with ivabradine (P ϭ 0.057 vs. MI rats). mRNA expression for KChIP2 (␤-subunit of the channel) was markedly and significantly (P Ͻ 0.05) enhanced in MI rats vs. sham with a trend to recover the control value in MIϩIVA (Fig. 3D) .
Cardiac energy metabolism. As expected, cardiac energy metabolism was profoundly affected by MI (Fig. 4) . Accordingly, CP was significantly decreased by 37% vs. sham (P Ͻ 0.001) and ATP by 18%. As a consequence, there was accumulation of ADP and AMP, which increased by 34% (P Ͻ 0.05 vs. sham) and 92% (P ϭ 0.097), respectively. This translated into a reduction in energy charge (Ϫ10%, P Ͻ 0.01 vs. sham). Treatment with ivabradine restored CP content by 33% (P Ͻ 0.001 vs. MI rats) and ATP by 15%; it reduced ADP content by 16% (P Ͻ 0.05) and tended to reduce AMP content (37%). Energy charge was maintained at the sham level with ivabradine (ϩ9%, P Ͻ 0.05 MIϩIVA vs. MI rats).
Correlation with HR. A number of parameters were investigated for correlation with HR (Fig. 5) . Thus despite the relatively small number of experiments, a significant inverse correlation was found between CP and HR (r ϭ Ϫ0.69, P ϭ 0.013) and a positive significant correlation between ADP and HR (r ϭ 0.77, P ϭ 0.003), constituting further evidence that the effect on cardiac metabolism is attributable to the HRreducing properties of ivabradine. Positive correlations with HR were also found for hydroxyproline (r ϭ Ϫ0.57, P ϭ 0.055) and ANP (r ϭ Ϫ0.52, P ϭ 0.003), and a negative correlation was found between HR and LVEF (r ϭ Ϫ0.40, P Ͻ 0.05).
DISCUSSION
We found that HR reduction with ivabradine prevents at least some of the post-MI maladaptations leading to remodeling and, eventually, HF. We made an effort to determine in the same animal model the global phenotype of post-MI remodeling, including hemodynamic, electrophysiological, structural, and energetic changes, as well as markers of HF.
HR is a major determinant of myocardial oxygen delivery and consumption. HR reduction optimizes energy balance by prolonging diastolic duration and improving diastolic coronary flow and oxygen supply, while simultaneously reducing cardiac work and oxygen demand (16) . The cardiac effects of ivabradine are highly specific to HR reduction, as it has no inotropic effects or impact on peripheral vascular resistance. This implies that HR reduction is the only active mechanism for ivabradine in our experimental model (40) .
The present data demonstrate that HR reduction improves the energetic state of the heart in terms of maintenance of the high-energy phosphate content (CP and ADP), and energy charge. In a similar model of post-MI animals, Christensen et al. (13) found that coronary reserve was improved with ivabradine but not with atenolol. This indicates a complementary mechanism by which ivabradine may improve oxygen supply and demand.
The improved myocardial energetics are concomitant to changes in cellular electrophysiological remodeling. As the main current to be modified in post-MI LV dysfunction, I to current density constitutes an excellent electrophysiological marker of LV remodeling (2, 44). Moreover, despite a large regional variability, a homogeneous reduction of I to density in all ventricular compartments (LV free wall and apex, septum, and right ventricle) has been reported in MI rats (1). Electrophysiological adaptation to post-MI LV dysfunction has been previously studied in human cardiomyocytes and, like in our experiments, shown to lead to a prolongation of APD and a reduction in I to current density (4). Our results demonstrate that HR reduction with ivabradine improves I to current density in the failing rat heart and prevents LV remodeling. We also observed a shortening of APD with ivabradine vs. the MI rats, which returns toward normal (sham) values. Whereas a small fraction of I to is attributable to Kv1.4, a large portion of the current is carried by channels in the Kv4 family. These channels are multimeric complexes consisting of pore-forming Kv4.2 and/or Kv4.3 proteins and auxiliary KChIP2 subunits. The Kv4.2 mRNA level appears to correlate well with the size of I to across the LV walls of rat and mouse hearts (19, 23) . Indeed, this recovery of APD was, at least in part, regulated at a transcriptional level because Kv4.2, one of the major genes encoding for the transient outward potassium channel in the rat, was also increased. Also, the ␤-subunit KChip2, which is thought to modulate transient outward current kinetics, was increased in MI and normalized to control values in MIϩIVA. A full appreciation of this result is impossible because to date the role of KChip subunits has not been fully elucidated; however, KChIP2 overexpression in rat hypertrophied hearts seems to negatively modulate I to , by slowing down current inactivation (22) . The energetic and electrophysiological improvements occur concomitant to a positive impact of ivabradine on LV function, with decreased LV volumes and increased EF. However, the effect of HR reduction on structural remodeling is large but less prominent on systolic function, as would be anticipated given that ivabradine was administered in the chronic phase and not acutely (therefore not reducing infarct size). There was also maintenance of CO with ivabradine, suggesting that HR reduction improves hemodynamics. Previous studies have shown that HR reduction with ivabradine also reduces wall stress (30) , leading to improved myocardial oxygen supply and demand (17) . Moreover, in our study, significant correlations were found between HR and markers of cardiac metabolism (CP and ADP) as well as markers of HF, such as hydroxyproline and ANP. Treatment with ivabradine also reduced plasma BNP levels, but this did not reach statistical significance. This indicates a direct link between HR reduction, energy consumption, interstitial remodeling, and neuroendocrine activation.
Our results appear to contradict those of ivabradine in a rat model of HF induced by pressure overload (14) . Banding of the ascending aorta induces a stenosis that increases the afterload on the heart and prevents any modification of SV. The elevated wall stress in such a model also increases myocardial oxygen consumption; under these conditions, HR reduction can only further reduce CO, increasing neuroendocrine activation and the progression of remodeling (14) . On the other hand, LAD ligation, as performed in our study, is a better model for investigation of the effects of HR reduction post-MI LV dysfunction because the afterload is not fixed, allowing the full benefits of HR reduction to be observed.
The effects of ␤-blockers are well known and constitute a premise to this study. The effects of HR reduction only with ivabradine should have been compared with those of ␤-blockers, which are known to improve HF via, at least in part, a HR-lowering effect (24) . The pharmacodynamic action of ␤-blockade, however, is more complex, as these agents also have negative inotropic and other metabolic effects, which together are most likely responsible for the long-term beneficial effects. In this context, pure HR reduction with ivabradine has been previously compared with atenolol in a canine model of myocardial ischemia and stunning (32) . Our results appear to further substantiate the role of HR reduction alone in the progression of LV dysfunction.
In the present study, the positive action of ivabradine on LV volumes and LVEF are not as immediate as in the canine model of stunning (32); they are evident at 90 days but not at 30 days. This suggests that the impact of ivabradine is not immediate like in stunning. Stunning and remodeling are, however, two different phenomena. Stunning refers to a delayed functional recovery of the ischemic myocytes after a short period of reversible ischemia without necrosis (7). In contrast, remodeling describes functional, biochemical, and structural changes occurring in the still viable myocytes following an acute (and usually large) MI with necrosis. Furthermore, in the stunning experiments, ivabradine was administered acutely either before ischemia and/or at the time of reperfusion (32) . This effect represents a cardioprotection against ischemia and/or reperfusion insult. In the present experiments, ivabradine was provided in the drinking water a week after coronary ligation to avoid any possible interference attributable to its cardioprotective effect on acute ischemia. The change in phenotype in the chronic phase of remodeling is not expected to be immediate, and HR reduction with ivabradine most likely requires time to exert a full beneficial antiremodeling effect. The ligated rat model correlates well with results in patients with coronary artery disease who are prone to develop remodeling and progression to HF. Interestingly, in a preliminary study in HF patients, ivabradine reduced ventricular volumes and improved LVEF (26) . A substudy of the MorBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) trial (20) is presently investigating the effect of ivabradine on remodeling measured in terms of centralized echocardiographic parameters in a subgroup of almost 1,000 patients participating in that study and may provide the clinical equivalent of our experiments. We should also note that the BEAUTIFUL patients had a long history of MI, on average 6 years previously (43), whereas our experimental conditions demonstrate a beneficial effect for ivabradine on early post-MI remodeling. The recent results of the systolic HF treatment with the I f inhibition ivabradine (SHIFT) trial demonstrate an advantage of ivabradine on HF-related outcomes (41) . Our results may constitute a pathophysiological basis for these effects in humans.
There are a number of limitations to the study. One could be the age of the rats because young rats continue to grow and mature, and cardiac responses to ivabradine may be significantly different from those in older animals. On the other hand, available data support the notion that 2.5-mo-old rats may be considered as "young adult" rather than "young" animals from an electrophysiological point of view. For example, electrophysiological maturation is complete within 1 mo of age (11, 38) .
In conclusion, myocardial injury and necrosis induce several changes in the still viable myocytes, normally referred to as remodeling. In the post-MI rat with LV dysfunction, the HR-reducing properties of ivabradine prevent the changes in the global phenotype of LV remodeling, optimize energy consumption, and avoid electrophysiological and structural modification.
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